Join Now

Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs

Posted in BioUtah News | Tagged | Comments Off on M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

The Future Of Inflammation: The Inflammasome And Beyond

Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature.

Posted in BioUtah News | Tagged | Comments Off on The Future Of Inflammation: The Inflammasome And Beyond

Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus

Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal.

Posted in BioUtah News | Tagged | Comments Off on Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus

Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer’s Disease at Discovery Europe 2024

Dr. Bearss will be the Chair of the “Drug Discovery for Neurodegenerative Diseases” session, on May 23.

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer’s Disease at Discovery Europe 2024

BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics

BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics

Posted in BioUtah News | Tagged | Comments Off on BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics

Halia Therapeutics to Present at BIO-Europe Spring 2024 Conference

Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics to Present at BIO-Europe Spring 2024 Conference

Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI- Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation

This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2)

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI- Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation

Halia Therapeutics co-founder David J. Bearss Featured in Utah Business

Utah Business recently featured Halia Therapeutics co-founder David Bearss in their Founder Series

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics co-founder David J. Bearss Featured in Utah Business

Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit

Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit

BioTuesdays Features Halia Therapeutics CEO

In a recent interview with BioTuesdays, Halia and Co-Founder David Bearss, P.HD., said that the company is “growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.” Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential […]

Posted in BioUtah News | Tagged | Comments Off on BioTuesdays Features Halia Therapeutics CEO